Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Hims & Hers Health (HIMS) is trending, with shares up 38.6% over the past month, significantly outperforming the S&P 500. The positive momentum is supported by substantial earnings estimate revisions, with the current quarter expected to show EPS of $0.17, a 183.3% year-over-year increase, and revenue growth for the current quarter estimated at 74.3%; the company's Zacks Rank is currently #2 (Buy), suggesting near-term outperformance.

Analysis

Hims & Hers Health, Inc. (HIMS) has demonstrated significant investor interest, evidenced by its stock's +38.6% return over the past month, substantially outperforming the S&P 500 composite's +6.1% gain and the Zacks Medical Info Systems industry's +16.9% rise. This strong performance is underpinned by robust fundamental outlooks, particularly in earnings estimate revisions. Analysts project current quarter earnings of $0.17 per share, a +183.3% year-over-year increase, with the Zacks Consensus Estimate having risen by +13% in the last 30 days. For the current fiscal year, expected EPS is $0.72 (+166.7% YoY), an estimate that has increased by +12.2% recently, and for the next fiscal year, EPS is forecasted at $1.06 (+46.3% YoY), with a +7.4% upward revision in the past month. This positive earnings trajectory has contributed to a Zacks Rank #2 (Buy). Revenue growth forecasts are equally compelling, with a consensus sales estimate of $550.03 million for the current quarter (+74.3% YoY), and full-year estimates of $2.34 billion (+58.4% YoY) for the current fiscal year and $2.88 billion (+23.3% YoY) for the next. The company's last reported quarter saw revenues of $586.01 million (+110.7% YoY) and EPS of $0.20, beating consensus estimates by +8.9% and +66.67% respectively. HIMS has consistently topped revenue estimates over the last four quarters and surpassed EPS estimates twice. Despite this strong growth, its Zacks Value Style Score of C suggests the stock is trading at par with its peers, indicating that current market enthusiasm is largely driven by its growth prospects rather than deep undervaluation.

Key Decisions for Investors

• Given the strong upward earnings estimate revisions and substantial revenue growth forecasts, investors may find HIMS an attractive opportunity, particularly with its Zacks Rank #2 (Buy) suggesting potential near-term outperformance.
• The company's consistent history of exceeding revenue expectations and recent significant earnings beats provide a degree of confidence in its operational execution, though sustained high growth will be critical to watch.
• While the stock's valuation is considered at par with peers, the significant growth trajectory in both earnings and revenue could justify its current levels for growth-focused portfolios, but investors should monitor for any deceleration in these key metrics.